discontinuation of second generation tyrosine kinase inhibitors
Download
Skip this Video
Download Presentation
Discontinuation of second generation tyrosine kinase inhibitors

Loading in 2 Seconds...

play fullscreen
1 / 17

Discontinuation of second generation tyrosine kinase inhibitors - PowerPoint PPT Presentation


  • 176 Views
  • Uploaded on

Discontinuation of second generation tyrosine kinase inhibitors. Dr Delphine Rea Service des Maladies du Sang Hôpital Saint-Louis Paris, France Fi-LMC (France Intergroupe-Leucémies Myéloïdes Chroniques). CML and MPDs UK national meeting Newcastle, March 1 st , 2013.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Discontinuation of second generation tyrosine kinase inhibitors' - tyme


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
discontinuation of second generation tyrosine kinase inhibitors

Discontinuation of second generation tyrosine kinase inhibitors

Dr Delphine Rea

Service des Maladies du Sang

Hôpital Saint-Louis

Paris, France

Fi-LMC (France Intergroupe-Leucémies Myéloïdes Chroniques)

CML and MPDs UK national meeting

Newcastle, March 1st, 2013

current goals of tki therapy
Current goals of TKI therapy

« Induction » phase

« Lifelong maintenance »

CP-CML at

Diagnosis

Near-normal life expectancy

PFS

EFS

CHR,

Minor CyR

PCyR

CCyR

MMR

Leukemic burden

Stable or improving MMR

> M18

M3

M6

M12

M18

Treatment change upon lack or loss of an optimal response, progression or unacceptable side effects

Time on TKI therapy

Baccaraniet al. JCO 2009; 27: 6041-6051

Björkholm et al. JCO 2011: 2514-2420

Gambacorti-Passerini et al. JNCI 2011; 103: 553-561

evidence that tkis may not be curative
Evidence that TKIs may not be curative
  • Primitive CD34+CD38- BCR-ABL+ cells are insensitive to imatinib-, dasatinib-, nilotinib- and bosutinib-induced cell death in vitro1-4
  • CD34+CD38- BCR-ABL+ cells escape from TKI-induced cell death is independent from BCR-ABL in vitro5
  • CD34+CD38- BCR-ABL+ residual cells in optimal responders to imatinib survive independently from BCR-ABL and possess in vivo repopulating capacities in mice6

1Graham et al. Blood 2002; 99: 319-325

2Copland et al. Blood 2006; 107: 4532-4539

3Jorgensen et al. Blood 2007; 109: 4016-4019

4Konig et al. Blood 2008; 111: 2329-2338

5Corbin et al. JCI 2011; 121: 396-406

6Hamilton et al. Blood 2012; 119: 1501-1510

median bcr abl is transcript levels over 84 months in the iris trial
Median BCR-ABL (IS) transcript levels over 84 months in the IRIS trial

0.003%

0.004%

Hughes et al. Blood 2010; 116: 3758-3765

stim stopping imatinib is feasible
STIM: Stopping imatinib is feasible

CP-CML

Imatinib≥3 years

Undetectable BCR-ABL≥2 years

1.0

Survival without molecular relapse:

39% (95% CI: 29-48) at 24 and 36 months

0.9

0.8

0.7

0.6

Survival without molecular relapse

0.5

0.4

0.3

0.2

Molecular relapses: n=61

0.1

Median follow-up: 34 months (9-50)

0.0

0

3

6

9

12

15

18

21

24

27

30

33

36

39

42

45

48

51

54

57

60

Months since discontinuation of imatinib

Undetectable BCR-ABL: at least 50 000 copies of the ABL control gene

Molecular relapse:defined by 2 positive RQ-PCR results over 1 month showing a significant rise

in BCR-ABL transcripts; triggers imatinib resumption.

Mahon et al. Blood (ASH) 2011; 118: Abstract 603

factors potentially a ssociated w ith o utcome
Factors potentially associated with outcome

1Mahon et al. Blood (ASH) 2011; 118: Abstract 603

2Ross et al. Haematologica 2012; abstract 0189.

3Takahashi et al. Haematologica 2012; 97: 903-906

4Yhim et al. Leukemia Research 2012; 36: 689-693

rationale for 2g tki discontinuation
Rationale for 2G-TKI discontinuation
  • Dasatinib and nilotinib display increased potency in vitro against BCR-ABL compared with imatinib1
  • Dasatinib and nilotinib are efficient salvage therapies in patients with intolerance or resistance to imatinib2,3
  • Frontline dasatinib and nilotinib induce higher rates of deep molecular responses than imatinib4,5
  • Case reports on dasatinib cessation in 4 patients with imatinib-resistant CML with very low or undetectable BCR-ABL transcripts6,7

4Saglio et al. N Engl J Med 2010; 362: 2251-2259

5Kantarjian et al. N Engl J Med 2010; 362: 2260-2270

6Rea et al. Leukemia 2009; 23: 1158-1159

7Ross et al. Haematologica 2011; 96: 1720-1722

1O’Hare et al. Cancer Res 2005; 65: 4500-4505

2Shah et al. J ClinOncol 2008; 26; 3204-3212

3Kantarjian et al. Blood 2007; 110: 3540-3546

stop 2g tki study design
STOP 2G-TKI: study design

Primary endpoint: survival without loss of MMR

Molecular relapse: loss of MMR

Loss of MMR triggered treatment resumption

CP-CML

TKI therapy ≥ 3 years

2G-TKI frontline or

after imatinib intolerance

or resistance

D1

M12

M24

M36

M48

M60

Undetectable

BCR-ABL*

≥ 24 months

STOP

2G-TKI

Year 1

Year 2

Year 3-5

RQ-PCR

monthly

RQ-PCR

Every

2-3 months

RQ-PCR

Every

3-6 months

*Molecular monitoring performed in local laboratories filling international standardization requirements.

*20 000 copies of ABL at least.

baseline characteristics
Baseline characteristics

*ELN 2006 definition

Rea et al. Blood (ASH) 2012; 120: Abstract 916

survival without mmr loss
Survival without MMR loss

Median follow-up was 17 months (7-38)

16/39 patients lost MMR

Median time to MMR loss was 3 months (1-25)

STOP 2G-TKI

100

Month 12: 61.1% (95% CI: 45.6-76.6)

80

60

Survival without MMR loss %

40

20

0

0

6

12

18

24

30

36

42

KM analysis

Months since 2G-TKI discontinuation

Rea et al. Blood (ASH) 2012; 120: Abstract 916

outcome after mmr loss
STOP 2G-TKIOutcome after MMR loss
  • Median BCR-ABL transcript level at MMR loss:
    • 0.35% IS (0.12-1.95)
  • TKI therapy resumption in 15/16 patients
    • Median time between MMR loss and therapy resumption: 1 month (0-4)
    • Same 2G-TKI used prior to discontinuation in all patients but 1
  • No loss of CHR or progression to AP/BP
  • With a median follow-up of 7 (1-35) months after therapy resumption:
    • MMR regained in14 patients, median time to MMR 2 (1-6) months
    • Undetectable BCR-ABL transcripts in 14 patients after a median time of 4 months (3-10)

Rea et al. Blood (ASH) 2012; 120: Abstract 916

responsiveness to 2g tki upon therapy resumption patient case
STOP 2G-TKIResponsiveness to 2G-TKI upon therapy resumption: patient case

STOP DASATINIB

10

DASATINIB

RESUMPTION

1

MMR

0.1

BCR-ABL/ABL % IS

0.01

MR4.5

0.001

0.0001

0

6

12

18

24

30

36

42

48

54

60

66

Detectable BCR-ABL

Months since dasatinib-induced

undetectable BCR-ABL transcripts

Undetectable BCR-ABL

with at least 32000 copies of ABL

Dr D Rea, Hôpital Saint-Louis, Paris

factors associated with outcome
STOP 2G-TKIFactors associated with outcome

KM analysis, two-tailed logrank test

Rea et al. Blood (ASH) 2012; 120: Abstract 916

different outcomes of persistent lsc
BCR-ABL+

LSC

Different outcomes of persistent LSC

CML disease relapse

Mat

Mat

Self renewal

Mat

Ph+ LSC-

driven hematopoiesis

STOP

TKI

Pre

Mat

Pre

Pro

Pre

Pro

Deep and sustained

Molecular response

TKI +

Inhibited Ph+ LSC-

driven hematopoiesis

No

CML disease

relapse

Survival

STOP

TKI

Why ?

CML-related

factors?

Therapy-related

factors?

Host-related

factors?

conclusions
Conclusions
  • Discontinuation of 2G-TKI in patients with deep and sustained molecular responses is possible without jeopardizing short-term outcome, under strict monitoring conditions.
  • TKI discontinuation may not be a realistic goal for all patients but the increasing use of 2G-TKI may broaden access to treatment discontinuation attempts.
  • Patients who successfully stop TKI may not be definitively cured, likely because of LSC persistence.
  • Unknown long-term risk of relapse, acquired resistance and progression to AP/BP after TKI discontinuation.
  • Targeting residual LSC with specific compounds may offer a chance for a definitive cure.
ad